Fortem Financial Group LLC Buys New Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Fortem Financial Group LLC purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 111,183 shares of the company’s stock, valued at approximately $772,000.

Several other institutional investors have also added to or reduced their stakes in GDRX. Rubric Capital Management LP lifted its stake in shares of GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after acquiring an additional 943,226 shares during the last quarter. Millennium Management LLC boosted its stake in shares of GoodRx by 36.5% during the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after purchasing an additional 1,102,758 shares during the period. American Century Companies Inc. purchased a new position in shares of GoodRx in the second quarter worth $18,183,000. Point72 Asset Management L.P. bought a new stake in GoodRx during the 3rd quarter valued at $11,295,000. Finally, Geode Capital Management LLC boosted its position in GoodRx by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock valued at $6,823,000 after buying an additional 58,610 shares during the period. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Citigroup decreased their price objective on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. Mizuho assumed coverage on GoodRx in a report on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 price objective for the company. Finally, Barclays reduced their target price on GoodRx from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.60.

GoodRx Trading Down 0.8 %

Shares of NASDAQ GDRX opened at $4.92 on Wednesday. The stock has a market cap of $1.88 billion, a P/E ratio of -164.00, a price-to-earnings-growth ratio of 3.57 and a beta of 1.29. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx Holdings, Inc. has a 1 year low of $4.09 and a 1 year high of $9.26. The firm has a 50-day moving average of $5.72 and a 200 day moving average of $7.13.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.